The short arm of chromosome 17 is associated with a large variety of copy number losses and gains, resulting from nonallelic homologous recombinations between low copy repeats, that lead to a number of well-characterized genomic disorders. To date, few cases of 17p13.1 microduplication have been reported [Belligni et al., 2012; Coutton et al., 2012; Kuroda et al., 2014; Mooneyham et al., 2014] , but a distinct phenotype has not yet been defined. Intellectual disability was observed in all patients as the hallmark feature. In addition, a wide range of clinical signs have been reported such as behavioral anomalies, dysmorphisms, obesity, and endocrinological abnormalities. On the contrary, the corresponding 17p13.1 microdeletion syndrome is well described, and its relationship with neurodevelopmental delay was established [Komoike et al., 2010; Carvalho et al., 2014] . Indeed, it has been proposed that alteration of dosage-dependent genes may be involved in the genesis of neurodevelopmental disorders in patients with overlapped microdeletions and microduplications of 17p13.1 [Belligni et al., 2012; Coutton et al., 2012; Mooneyham et al., 2014] . Comparing the genetic profiles of cases of 17p13.1 microduplications published up to 2014, Mooneyham et al. [2014] identified a common region of overlap including the DLG4 , GABARAP , and CTDNEP1 genes as the candidate genes for intellectual disability in these patients.
Here, we describe a male patient with a 17p13.1 microduplication who, along with intellectual disability, facial dysmorphisms and obesity, presented with some previously unreported characteristics such as synoprhys, short hyperconvex nails, stiffness of interphalangeal hand joints, and motor dyspraxia. Specifically, we underline that endocrinological abnormalities are important features which have to be researched and closely monitored. Moreover, we attempted to describe a common clinical phenotype for 17p13.1 microduplication syndrome comparing the clinical and genetic aspects of the cases currently described.
Patient and Methods

Clinical Report
The propositus is a 13-year-old boy. He is the second child of healthy unrelated parents of Chinese ancestry. The family history of intellectual disability, diabetes, obesity or other endocrine conditions was negative. He was born at 38 weeks' gestation by spontaneous vaginal delivery after an uneventful pregnancy, and he weighed 2,700 g. Early neonatal adaptation was normal. During infancy and early childhood, the boy presented psychomotor developmental delay. His speech onset was at 3 years of age and was limited to a few words and simple sentences with some speech impediments. At the age of 7 years, when the boy moved to Italy, mild intellectual disability (IQ 58) was documented.
Since infancy, food hoarding was observed which led to obesity. At the time of clinical evaluations, between 11 and 13 years of age, he showed marked hyperactivity and good social interaction skills despite communication difficulties and motor clumsiness.
At the age of 12 years, physical examination revealed: height 155 cm (75-90th percentile), weight 54 kg (97th percentile), and head circumference 54 cm (75-90th percentile). His BMI was 23.4, compatible with obesity [Cole et al., 2000] . Dysmorphic features included a flat occiput, low posterior hairline, rounded face, synophrys, upslanting palpebral fissures, a small nose with upturned nostrils, An ultrasound of the abdomen at 12 years showed a moderate hepatic fatty liver, with normal liver function tests compatible with nonalcoholic fatty liver disease. Other causes of liver disease were ruled out.
Endocrine and metabolic investigations showed increased hemoglobin A1c and borderline fasting blood glucose levels. Therefore, a 5-time point oral glucose tolerance test was performed revealing severe hyperinsulinism (peak 330.4 μIU/ml) and glucose intolerance (blood glucose at 120 min 139.2 mg/dl). Investigations for any autoimmune diseases were negative [Uwaifo et al., 2002] . A 6-month lifestyle intervention normalized the patient's hemoglobin A1c, and his BMI was reduced to 22.53 (overweight).
The boy's fundus oculi was normal, whereas the evaluation of his ocular motility documented prominent exotropia of the left eye. A chromosome analysis revealed a normal male karyotype.
Methods
Array-CGH Analysis
Screening of genomic rearrangements was performed by array-CGH using a Human Genome CGH Microarray kit 8 × 60K (Agilent Technologies, Santa Clara, Calif., USA) according to standard procedures. This analysis revealed a genomic duplication encompassing a 1,56-Mb region, from A_14_P132798 (6,482,088 bp) to A_14_P122419 (8,047,770 bp) (GRCh37/hg19 assembly) in chromosome 17p13.2p13.1. The region harbors 89 RefSeq genes. No additional aberrations were detected. Both parents were found to have a normal karyotype and CGH profile indicating that the duplication on chromosome 17 originated de novo in the son ( fig. 2 A) .
FISH Analysis FISH analysis using TP53 probe localized to 17p13.1 and probe D17Z1 for the centromeric region of chromosome 17 (Aquarius) was performed on interphase nuclei ( fig. 2 B) and metaphase chromosomes ( fig. 2 C) of peripheral blood cells samples obtained from the patient and parents following the manufacturer's protocol. The analysis confirmed the presence of a tandem duplication in chromosome 17. No duplications or translocations were present in his parents. FISH analysis of both parents was normal. 
Results and Discussion
Five 17p13.1 microduplication cases have recently been described in the literature and were characterized by intellectual disability and other variable clinical signs [Belligni et al., 2012; Coutton et al., 2012; Kuroda et al., 2014; Mooneyham et al., 2014] . The first reported case was a 15-year-old boy with moderate intellectual disability, non-febrile seizures, hypothyroidism, type 2 diabetes mellitus, hypertriglyceridemia, and astigmatism. His dysmorphic features included thin eyebrows, a bulbous nasal tip, long and smooth philtrum, malar hypoplasia, thin upper lip, micrognathia, and a short neck. Brain MRI detected choroid plexus cysts. A de novo duplication encompassing 790-830 kb (7, 016, 807, 789) in 17p13.1 was identified [Belligni et al., 2012] .
The second case was a 4-year-old boy with developmental and speech delay, growth retardation, relative [Coutton et al., 2012] . The third reported case was a 9-year-old girl affected by prenatal growth retardation, hypotonia, mild intellectual disability (IQ 50-58), and onset of obesity at the age of 7 years. Her face was coarse with wide palpebral fissures, upturned nostrils, and long mandible. Array-CGH analysis revealed a de novo 3.2-Mb duplication (6, 013, 214, 914) in 17p13.1 [Kuroda et al., 2014] .
The last 2 patients were reported by Mooneyham et al. [2014] . They described a 2-year-old boy with neurodevelopmental delay, macrocephaly, hypotonia, nystagmus and hyperopia. His facial features included a high anterior hairline, broad forehead, triangular face, flat occiput, broad nasal tip, full lips, openmouthed expression, and mild micrognathia. Microarray analysis identified a de novo 134-kb duplication (7, 551, 685, 368) in chromosome 17p13.1 and a de novo 788-kb duplication (6, 610, 399, 323) in chromosome 17p13.2p13.1. The second patient described was a 29-year-old woman with mild intellectual disability, hyperactive disorder, food hoarding, seizures, hypertension, type 2 diabetes mellitus, and dyslipidemia. Her dysmorphic features included a high anterior hairline, broad nasal tip, full lips, mild micrognathia, and prominent antihelix with unfurled helix. A 62.5-kb duplication (7, 034, 097, 308) in chromosome 17p13.1 of unknown origin was detected [Mooneyham et al., 2014] .
We made a review of the literature and compared the data of all the patients reported to date, in order to delineate a typical phenotype of the 17p13.1 microduplication syndrome ( table 1 ). The 2 patients reported by Belligni et al. [2012] and Coutton et al. [2012] were re-examined in their clinical presentation; for the patients reported by Kuroda et al. [2014] and Mooneyham et al. [2014] , we used the data reported in the published articles.
Intellectual disability/neurodevelopmental delay was the hallmark feature observed in all patients. The dysmorphic features in all cases were rather variable; therefore, it was difficult to delineate a common facial gestalt. Micrognathia was the most frequent facial feature in cases described so far (5/6 cases). Broad nasal tip was seen in 4 out of 6 cases, whilst rounded face, upslanting palpebral fissures, and full lips were present in half of the cases. Endocrine disorders were frequently reported, in particular obesity (4/6), dyslipidemia (4/6) and type 2 diabetes mellitus (3/6). In the patients presenting with endocrine disorders, clinical symptoms were evident as early as the second half of the first decade of life. Hyperactivity and food hoarding were seen in 4 out of 6 reported patients to date.
Three out of 6 patients showed abnormalities on brain MRI. Since all of the observed abnormalities were different, encompassing enlarged extra-axial spaces, hippocampal malrotation, reduced gyration, choroid plexus cysts, it is difficult to say whether 'brain MRI anomalies' are a typical feature of this condition.
Our patient is the first case who presented with synophrys, short hyperconvex nails, stiffness of hand joints and motor dyspraxia. These expand the spectrum of features of the 17p13.1 duplication syndrome.
The variable size of the duplicated regions and the different genes involved may explain the heterogeneous clinical presentation amongst the patients.
The exact variation of the genomic CNV seen in the present case has not been reported in the CNV database to date. It involves numerous genes, with the majority of them already previously noted to have a significant role in the 17p13.1 microduplication phenotype. Several candidate genes for intellectual disability in the 17p13.1 region have been identified so far, including DLG4 (discs large MAGUK scaffold protein; MIM 602887), GABARAP (GABA type A receptor associated-protein like 1; MIM 605125), FXR2 (FMR1 autosomal homolog 2; MIM 605339), NLGN2 (neuroligin 2; MIM 606479), and EFNB3 (ephrin B3; MIM 602297) [Belligni et al., 2012; Coutton et al., 2012; Kuroda et al., 2014] . Most of these genes have also been previously studied in 17p13.1 microdeletion syndrome, suggesting their role in the mental impairment of these patients [Krepischi-Santos et al., 2009; Komoike et al., 2010; Carvalho et al., 2014] . Mooneyham et al. [2014] , comparing their 2 cases with the 2 previously reported patients, defined a common region of overlap, which included DLG4 , GABARAP , and CTDNEP1 as the candidate genes for intellectual disability in patients with 17p13.1 microduplications.
Using the UCSC genome browser (GRCh37/h19), we extended the comparison of the minimal critical region to include our case and the one reported by Kuroda et al. [2014] . We identified a region overlapping with that described by Mooneyham et al. [2014] which included 7 genes ( fig. 3 ) . Some of these genes have been suggested to be implicated in neurodevelopment impairment; however, the available data are still unclear. Therefore, this linkage is still to be elucidated.
Most of the reported duplicated regions also contain genes associated with the metabolism of carbohydrates. In particular, SLC2A4 (the insulin-responsive glucose transporter) could be involved in the 17p13.1 phenotype because its impaired regulation has been associated with diabetes mellitus and obesity [Belligni et al., 2012; Kuroda et al., 2014] . This gene is placed just proximal to the minimal critical region identified for the 17p13.1 microduplication syndrome. Both glucose intolerance and fatty liver diseases are an expression of metabolic complications of obesity; however, in these patients, as the deletion involves GLUT4 , this could account for both metabolic features in addition to obesity [Kim et al., 2014] .
The second case described by Mooneyham et al. [2014] affected by type 2 diabetes mellitus and obesity had a small duplicated region, corresponding to the minimal critical region, not including SLC2A4 . We propose a possible position effect to explain the woman's phenotype. To date, 4/6 patients are obese, and 3 of them developed diabetes. The remaining 2 patients have not shown signs of obesity to date. Keeping in mind that all of the reported cases with obesity became obese at a later age, it possibly could be still too early to evaluate the case reported (chr17: 7,094,072-7,156,584 [hg19] ) identified in the present case and the previous cases reported by Belligni et al. [2012 ], Coutton et al. [2012 , Kuroda et al. [2014] , and Mooneyham et al. [2014] . The horizontal black bars show the duplicated regions of patients involved. The red box (bottom) shows the 7 genes located within the minimal region of overlap.
by Mooneyham et al. [2014] regarding the child was 2 years old at the time of the report. We suppose that these clinical signs could become evident later in life. The patient reported by Coutton et al. [2012] presented growth deficiency since the prenatal period. Moreover, he required growth hormone treatment from the age of 4 years. Based on current knowledge, growth retardation seen in this patient could either be the part of the 17p13.1 microduplication syndrome or could be caused by some other unrecognized condition.
In conclusion, 17p13.1 microduplications appear to share common features such as intellectual disability, obesity, and endocrine disorders. All patients described to date had variable facial dysmorphisms; therefore, a characteristic facial gestalt was not definable. The present and previously reported cases of 17p13.1 microduplication do not disclose common breakpoints, but we can identify a minimal common region, whose genes are probably involved with the neurodevelopmental phenotype. Finally, we cannot ignore the presence of genes associated with metabolism as well as the endocrinological phenotypes described in most microduplicated regions reported. So we underline the need to monitor endocrinological aspects in patients with 17p13.1 microduplication.
